Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 ...
Intends to file definitive proxy materials in the coming days SINOVAC’s Board of Directors (the “SINOVAC Board”) also issued a letter to shareholders. The full text of the letter follows: Dear SINOVAC ...
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today sent shareholders ...
Accelerates payment of previously announced special cash dividend of US$55.00 per common share Decides to declare second special cash dividend of US$19.00 per common share Intends to declare third ...
Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced it filed its annual report on Form 20-F for the fiscal year ...
Dec 31 (Reuters) - Sinovac's two-dose COVID-19 vaccine followed by a booster Pfizer-BioNTech shot showed a lower immune response against the Omicron variant compared with other strains, according to a ...
(RTTNews) - China-based SINOVAC Biotech Ltd. (SVA) Monday announced that its Board of Directors has alerted shareholders to a new lawsuit by Advantech/Prime Success, which threatens to prevent payment ...
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
Amid global efforts to scale up vaccine capacity during the pandemic, China's Sinovac and a partner in South Africa are reportedly in talks to build a manufacturing facility in the country to produce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results